What Researchers Did
Researchers systematically reviewed 6 randomized controlled trials involving 7508 normoxemic patients with acute coronary syndrome to evaluate the role of supplemental oxygen therapy.
What They Found
High-concentration oxygen therapy did not significantly decrease all-cause mortality within 1 year (odds ratio, 1.01; 95% CI, 0.81-1.25; P = .95) compared to ambient air or titrated oxygen. Furthermore, it did not significantly reduce myocardial infarct size, as measured by peak cardiac troponin (mean difference, -0.53 ng/mL; P = .12) or magnetic resonance imaging (mean difference, 1.45 g; P = .39).
What This Means for Canadian Patients
For Canadian patients experiencing acute coronary syndrome who are normoxemic, high-concentration oxygen therapy may not offer additional benefits in reducing mortality or infarct size. This suggests that clinicians should carefully consider the necessity of supplemental oxygen in these patients, potentially avoiding unnecessary interventions.
Canadian Relevance
This systematic review did not include any studies with a specific Canadian connection.
Study Limitations
A limitation is that not all included studies reported on every primary and secondary outcome, potentially limiting the comprehensive assessment of all effects.